CoChat

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population

Open access
Funch, Donnie, Mortimer, Kathleen, Ziyadeh, Najat J, Seeger, John D, Zhou, Li, Ng, Eva, Ross, Douglas, Major-Pedersen, Atheline, Bosch-Traberg, Heidrun, Gydesen, Helge, Dore, David · 2021 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Quantify association between the glucagon-like peptide-1 receptor agonist liraglutide and risk of thyroid cancer (TC) compared to other antidiabetics. PATIENTS AND METHODS: Initiators of liraglutide, exenatide, metformin, pioglitazone or groups of dipeptidyl peptidase-4 inhibitors or sulfonylureas were identified in a US health plan (2010-2014) and followed for a median of 17 months. Thyroid cancer cases during follow-up were identified via a validated algorithm. Incidence rates of TC among liraglutide and comparators were assessed using relative risks estimated within propensity score-matched cohorts using intention to treat (ITT) and time on drug analyses. Latency effects and potential surveillance bias were evaluated. RESULTS: Relative risks from ITT analyses ranged from 1.00 (95% confidence interval (CI) 0.56-1.79) versus metformin to 1.70 (95% CI 1.03-2.81) versus all comparators excluding exenatide. Effect estimates from latency analyses were slightly attenuated. Time on drug analyses suggested no increased risk for either longer duration or higher cumulative dose of liraglutide. Medical record review found 85% were papillary or a follicular variant of papillary or both; 46% were microcarcinomas (≤10 millimeters), which were more prevalent in the liraglutide cohort (67% versus 43% in all comparators). CONCLUSION: Relative risks were elevated for several comparisons, which should be interpreted cautiously because of potential residual confounding and surveillance bias. Liraglutide cases had smaller thyroid nodules and shorter time-to-diagnosis, suggesting increased surveillance for TC among liraglutide initiators, especially shortly after the drug´s approval. After adjusting the primary analyses (ITT) for latency, no significant elevated risk of TC was observed among liraglutide initiators.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dmso.s305496

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Propensity score matched ITT and TOD analyses for thyroid cancer.
Figure 1 Propensity score matched ITT and TOD analyses for thyroid cancer.CC BY-NC · PubMed Central
Figure 2 Proportion of thyroid cancer cases diagnosed since cohort entry by year of initiation.
Figure 2 Proportion of thyroid cancer cases diagnosed since cohort entry by year of initiation.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Paper 214-26 in proceedings of the twenty-sixth annual SAS users group international conference. Long Beach, California: SAS Institute, Inc; 2001. Available from: http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Accessed November 01, 2019.

Cited by

See all 24

Metadata

Authors
Funch, D., Mortimer, K., Ziyadeh, N. J., Seeger, J. D., Zhou, L., Ng, E., Ross, D., Major-Pedersen, A., Bosch-Traberg, H., Gydesen, H., & Dore, D.
Affiliations
  • Harvard University (US)
  • Novo Nordisk (Denmark) (DK)
  • Brown University (US)
Corresponding author
Ziyadeh, Najat J
Venue
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Published
2021-06
Volume
Volume 14
Pages
2619-2629
ISSN
1178-7007 (ISSN-L)
OpenAlex
W3171649840
Cited by
24
References
37
Citations by year
2026: 6 · 2025: 6 · 2024: 5 · 2023: 5 · 2022: 2
FWCI
0.94
Type
journal article
Language
en
Open access
Locations
  • Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
Novo Nordisk
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
liraglutide, thyroid cancer, GLP-1 receptor agonists, exenatide, metformin, pioglitazone, DPP-4 inhibitors, sulfonylureas, antidiabetic drugs, drug safety, papillary thyroid carcinoma, thyroid microcarcinoma, surveillance bias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.